戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d 238 of 1948 (12.2%) patients randomized to cinacalcet.
2 erparathyroidism with the calcimimetic agent cinacalcet.
3 ficantly more frequent in patients receiving cinacalcet.
4 etic etelcalcetide and the oral calcimimetic cinacalcet.
5 tal of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) tit
6  treatment were randomly assigned to receive cinacalcet (371 patients) or placebo (370 patients) for
7                 Among patients randomized to cinacalcet, a >/=30% reduction in FGF23 between baseline
8                                              Cinacalcet also significantly reduced serum calcium, pho
9 avenously and oral placebo (n = 340) or oral cinacalcet and IV placebo (n = 343) for 26 weeks.
10                                              Cinacalcet and NPS-2143 are allosteric CaSR activators a
11              This study investigated whether cinacalcet and NPS-2143 may rectify Ca(2+) i alterations
12                                              Cinacalcet and NPS-2143 rectified the Ca(2+) i responses
13 f 343 patients (57.7%) randomized to receive cinacalcet and the 232 of 340 patients (68.2%) randomize
14 nal disease phase at the time of transplant, cinacalcet, and native vitamin D were used significantly
15 athyroid hormone; and nutritional vitamin D, cinacalcet, and warfarin treatments were associated with
16 ared with younger patients and the effect of cinacalcet appeared more pronounced in older patients.
17                                              Cinacalcet appears to be an effective drug for the treat
18                  From nonrandomized studies, cinacalcet appears to be safe and effective for the trea
19 lues decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group
20 g an unadjusted intention-to-treat analysis, cinacalcet did not reduce the rate of clinical fracture.
21 n an unadjusted intention-to-treat analysis, cinacalcet did not significantly reduce the risk of deat
22 ld be more cost effective than cinacalcet if cinacalcet duration reached 14 months.
23                                              Cinacalcet effectively reduced parathyroid hormone level
24 firmed the efficacy of the oral calcimimetic cinacalcet for achieving long-term reductions in serum c
25 tal parathyroidectomy is more effective than cinacalcet for controlling hypercalcemia caused by persi
26 11 kidney transplant recipients treated with cinacalcet for hyperparathyroidism met inclusion criteri
27      At 12 months, ten of 15 patients in the cinacalcet group and 15 of 15 patients in the parathyroi
28 ached in 938 of 1948 patients (48.2%) in the cinacalcet group and 952 of 1935 patients (49.2%) in the
29 rse events were digestive intolerance in the cinacalcet group and hypocalcemia in the parathyroidecto
30 phorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo g
31                   Forty-three percent of the cinacalcet group reached the primary end point, as compa
32 in the placebo group (relative hazard in the cinacalcet group vs. the placebo group, 0.93; 95% confid
33 f study-drug exposure was 21.2 months in the cinacalcet group, versus 17.5 months in the placebo grou
34  larger proportion of patients randomized to cinacalcet had >/=30% (68% versus 28%) reductions in FGF
35                                              Cinacalcet had comparable efficacy in HD and PD patients
36                             The calcimimetic cinacalcet HCl acts on the calcium-sensing receptor to i
37 modialysis using data from the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events tr
38 d anilines as well as the bioactive compound Cinacalcet HCl.
39  and effectiveness of the calcimimetic agent cinacalcet hydrochloride.
40    Surgery would be more cost effective than cinacalcet if cinacalcet duration reached 14 months.
41 , subtotal parathyroidectomy was superior to cinacalcet in controlling hypercalcemia in these patient
42 d study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis
43 the use of etelcalcetide was not inferior to cinacalcet in reducing serum PTH concentrations over 26
44 identified studies evaluating treatment with cinacalcet in renal transplant recipients with hyperpara
45  There is limited experience with the use of cinacalcet in the treatment of persistent secondary hype
46                                              Cinacalcet lowers parathyroid hormone levels and improve
47 d that treatment with the calcimimetic agent cinacalcet might reduce the risk of death or nonfatal ca
48 otal, 30 patients were randomized to receive cinacalcet (n=15) or subtotal parathyroidectomy (n=15).
49                                              Cinacalcet offers a new therapeutic option for controlli
50             Etelcalcetide was noninferior to cinacalcet on the primary end point.
51 ith secondary hyperparathyroidism to receive cinacalcet or placebo for </=64 months.
52 re undergoing hemodialysis to receive either cinacalcet or placebo.
53 ared with 138 patients (40.2%) randomized to cinacalcet (P = .001; difference in proportions, 12.2%;
54 nts prompting discontinuation of study drug, cinacalcet reduced the rate of clinical fracture by 16%-
55                                              Cinacalcet resulted in hypocalcemia in seven patients.
56                               Treatment with cinacalcet significantly lowers serum FGF23.
57 fer (pH 7.4), and CaR-specific calcimimetic, cinacalcet, stimulated gastrin and acid secretion, where
58 tomy, transplant, or provision of commercial cinacalcet), the relative hazard was 0.71 (95% CI, 0.58
59  18 renal allograft recipients who initiated cinacalcet therapy from 1 month to 23 years (median 3 ye
60 sis of a randomized clinical trial comparing cinacalcet to placebo in addition to conventional therap
61 arathyroid hormone (PTH), IV vitamin D dose, cinacalcet use, and phosphate binder use.
62 yroid hormone, or C-reactive protein levels, cinacalcet use, or phosphate binder or calcitriol dose i
63  analysis, the relative hazard for fracture (cinacalcet versus placebo) was 0.89 (95% confidence inte
64 to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and
65 ong participants who remained untreated with cinacalcet, vitamin D sterols, or parathyroidectomy.
66 ng IV etelcalcetide vs oral placebo and oral cinacalcet vs IV placebo in 683 patients receiving hemod
67                              Once-daily oral cinacalcet was effective in rapidly and safely reducing
68    During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduc
69                We tested the hypothesis that cinacalcet would reduce the rate of clinical fractures i

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。